FinscoFinsco

CRISPR Therapeutics (US.CRSP)

Capital Allocation Audit · Period: 2014 – 2026

$Open the interactive terminal to run `audit` and explore all dimensions.→

Key Metrics

US.CRSP · YoY: 2026 Q1 vs 2025 Q1

MetricValueYoY
FCF Conversion100.5%→
ROE-6.8%↑
Cash Conversion-→
D/E Ratio0.43↓
Gross Margin-3082.9%↑
US.CRSP (CRISPR Therapeutics) | YoY: 2026 Q1 vs 2025 Q1


Metric              Value  YoY
------------------------------
FCF Conversion     100.5%    →
ROE                 -6.8%    ↑
Cash Conversion         -    →
D/E Ratio            0.43    ↓
Gross Margin     -3082.9%    ↑
Key Metrics
US.CRSP (CRISPR Therapeutics) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY
------------------------------
FCF Conversion 100.5% →
ROE -6.8% ↑
Cash Conversion - →
D/E Ratio 0.43 ↓
Gross Margin -3082.9% ↑

Audit Dimensions

Capital FlowReturnsEarning QualityDebt DisciplineMoat

Unlimited Companies

AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies